SG11201402765TA - THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES - Google Patents
THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASESInfo
- Publication number
- SG11201402765TA SG11201402765TA SG11201402765TA SG11201402765TA SG11201402765TA SG 11201402765T A SG11201402765T A SG 11201402765TA SG 11201402765T A SG11201402765T A SG 11201402765TA SG 11201402765T A SG11201402765T A SG 11201402765TA SG 11201402765T A SG11201402765T A SG 11201402765TA
- Authority
- SG
- Singapore
- Prior art keywords
- thieno
- inhibitory activity
- protein kinases
- pyrimidine derivatives
- pyrimidine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20110146818 | 2011-12-30 | ||
| PCT/KR2012/011571 WO2013100632A1 (en) | 2011-12-30 | 2012-12-27 | THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201402765TA true SG11201402765TA (en) | 2014-06-27 |
Family
ID=48697978
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201402765TA SG11201402765TA (en) | 2011-12-30 | 2012-12-27 | THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES |
| SG10201701999QA SG10201701999QA (en) | 2011-12-30 | 2012-12-27 | THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201701999QA SG10201701999QA (en) | 2011-12-30 | 2012-12-27 | THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US9156852B2 (en) |
| EP (2) | EP3617213A1 (en) |
| JP (1) | JP5797345B2 (en) |
| KR (1) | KR101490761B1 (en) |
| CN (1) | CN104039798B (en) |
| AR (1) | AR089489A1 (en) |
| AU (1) | AU2012363558C1 (en) |
| BR (2) | BR122019019582B1 (en) |
| CA (1) | CA2859668C (en) |
| CL (1) | CL2014001729A1 (en) |
| CO (1) | CO7010840A2 (en) |
| DK (1) | DK2797927T3 (en) |
| ES (1) | ES2751608T3 (en) |
| HK (1) | HK1200833A1 (en) |
| HR (1) | HRP20191840T8 (en) |
| HU (1) | HUE045957T2 (en) |
| IL (2) | IL233441B (en) |
| IN (1) | IN2014DN06101A (en) |
| LT (1) | LT2797927T (en) |
| MX (2) | MX363659B (en) |
| MY (1) | MY170988A (en) |
| PE (1) | PE20141404A1 (en) |
| PH (1) | PH12014501504B1 (en) |
| PL (1) | PL2797927T3 (en) |
| PT (1) | PT2797927T (en) |
| RS (1) | RS59420B1 (en) |
| RU (2) | RU2625799C2 (en) |
| SG (2) | SG11201402765TA (en) |
| SI (1) | SI2797927T1 (en) |
| TW (1) | TWI462927B (en) |
| UA (1) | UA109614C2 (en) |
| WO (1) | WO2013100632A1 (en) |
| ZA (1) | ZA201405583B (en) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2918588T3 (en) | 2010-05-20 | 2017-10-31 | Array Biopharma Inc | Macrocyclic compounds as TRK kinase inhibitors |
| TWI713455B (en) | 2014-06-25 | 2020-12-21 | 美商伊凡克特治療公司 | Mnk inhibitors and methods related thereto |
| US10040745B2 (en) | 2014-10-14 | 2018-08-07 | Syngenta Participations Ag | Process for the preparation of 1-(3,5-dichlorophenyl)-2,2,2-trifluoroethanone and derivatives thereof |
| EA035049B1 (en) | 2015-07-16 | 2020-04-22 | Аррэй Байофарма Инк. | SUBSTITUTED PYRAZOLO[1,5-a]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS |
| CA3002558A1 (en) | 2015-10-29 | 2017-05-04 | Effector Therapeutics, Inc. | Pyrrolo-, pyrazolo-, imidazo-pyrimidine and pyridine compounds that inhibit mnk1 and mnk2 |
| BR112018008714A2 (en) | 2015-10-29 | 2018-10-30 | Effector Therapeutics Inc | isoindoline, azaisoindoline, dihydroindenone and dihydroazaindenone inhibitors of mnk1 and mnk2 |
| US10000487B2 (en) | 2015-11-20 | 2018-06-19 | Effector Therapeutics, Inc. | Heterocyclic compounds that inhibit the kinase activity of Mnk useful for treating various cancers |
| CN106928252B (en) * | 2015-12-31 | 2019-09-27 | 成都先导药物开发股份有限公司 | A kind of compound and the preparation method and application thereof inhibiting ROCK |
| EP3414247B1 (en) | 2016-02-08 | 2021-04-21 | F. Hoffmann-La Roche AG | Spiroindolinones as ddr1 inhibitors |
| KR20180134347A (en) | 2016-04-15 | 2018-12-18 | 제넨테크, 인크. | Diagnosis and Treatment of Cancer |
| CN106153920B (en) * | 2016-07-25 | 2018-04-27 | 四川大学华西医院 | A kind of screening lung cancer kit |
| TWI704148B (en) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors |
| JOP20190077A1 (en) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors |
| WO2018122746A1 (en) * | 2016-12-28 | 2018-07-05 | Minoryx Therapeutics S.L. | Isoquinoline compounds, methods for their preparation, and therapeutic uses thereof in conditions associated with the alteration of the activity of beta galactosidase |
| EP3571203B1 (en) | 2017-01-18 | 2023-06-07 | Array BioPharma Inc. | Substituted pyrazolo[1,5-a]pyrazine compounds as ret kinase inhibitors |
| WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
| CN110719781A (en) | 2017-02-14 | 2020-01-21 | 效应治疗股份有限公司 | Substituted piperidine MnK inhibitors and methods related thereto |
| JOP20190213A1 (en) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | Macrocyclic compounds as ros1 kinase inhibitors |
| AU2018308038B2 (en) | 2017-07-28 | 2022-02-03 | Yuhan Corporation | Improved process for preparing aminopyrimidine derivatives |
| EP3679159A1 (en) | 2017-09-08 | 2020-07-15 | H. Hoffnabb-La Roche Ag | Diagnostic and therapeutic methods for cancer |
| TWI791053B (en) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | Crystalline forms of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile and pharmaceutical composition thereof |
| TWI812649B (en) | 2017-10-10 | 2023-08-21 | 美商絡速藥業公司 | Formulations of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile |
| BR112020010903A2 (en) * | 2017-11-30 | 2020-11-17 | Hanmi Pharm. Co., Ltd. | compound, salt of a compound of formula (I), pharmaceutical composition, use of a pharmaceutical composition, use of a compound, method of preparing a crystalline form of the salt |
| TWI803541B (en) * | 2017-11-30 | 2023-06-01 | 韓商韓美藥品股份有限公司 | Thieno[3,2-d]pyrimidine compound having inhibitory activity for protein kinase |
| TWI802635B (en) | 2018-01-18 | 2023-05-21 | 美商亞雷生物製藥股份有限公司 | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors |
| US11524963B2 (en) | 2018-01-18 | 2022-12-13 | Array Biopharma Inc. | Substituted pyrazolo[3,4-d]pyrimidines as RET kinase inhibitors |
| JP6997876B2 (en) | 2018-01-18 | 2022-02-04 | アレイ バイオファーマ インコーポレイテッド | Substituted pyrazolyl [4,3-C] pyridine compound as a RET kinase inhibitor |
| EP3752200A1 (en) | 2018-02-13 | 2020-12-23 | Vib Vzw | Targeting minimal residual disease in cancer with rxr antagonists |
| EP3762379A1 (en) | 2018-03-07 | 2021-01-13 | Bayer Aktiengesellschaft | Identification and use of erk5 inhibitors |
| CA3111984A1 (en) | 2018-09-10 | 2020-03-19 | Array Biopharma Inc. | Fused heterocyclic compounds as ret kinase inhibitors |
| EP3870178A4 (en) | 2018-10-24 | 2022-08-03 | Effector Therapeutics Inc. | Crystalline forms of mnk inhibitors |
| TW202038957A (en) | 2018-12-21 | 2020-11-01 | 日商第一三共股份有限公司 | Combination of antibody-drug conjugate and kinase inhibitor |
| CN110183464B (en) * | 2019-05-31 | 2021-08-31 | 淮阴工学院 | Anti-cancer compound estinib and synthesis method and application thereof |
| CA3178927A1 (en) | 2020-05-26 | 2021-12-02 | Hanmi Pharm. Co., Ltd. | Belvarafenib for use in cancer treatment |
| US11351149B2 (en) | 2020-09-03 | 2022-06-07 | Pfizer Inc. | Nitrile-containing antiviral compounds |
| KR20230096965A (en) | 2020-10-27 | 2023-06-30 | 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 | Arylamide compound, pharmaceutical composition containing the same, and preparation method and use thereof |
| JP2024509269A (en) | 2021-03-09 | 2024-02-29 | ジェネンテック， インコーポレイテッド | Bervarafenib for use in the treatment of brain cancer |
| JP2024514112A (en) | 2021-04-06 | 2024-03-28 | ジェネンテック， インコーポレイテッド | Combination therapy with bervarafenib and cobimetinib or combination therapy with bervarafenib, cobimetinib and atezolizumab |
| CN117202897A (en) | 2021-04-09 | 2023-12-08 | 基因泰克公司 | Combination therapy using RAF inhibitors and PD-1 axis inhibitors |
| WO2023278981A1 (en) | 2021-06-30 | 2023-01-05 | Genentech, Inc. | Synthesis of a bis-mesylate salt of 4-amino-n-(1 -((3-chloro-2- fluorophenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2- d]pyrimidine-7-carboxamide and intermediates thereto |
| CN114213430B (en) * | 2021-12-28 | 2022-12-02 | 深圳湾实验室 | Preparation method of 4-aminothiophene [3,2-d ] pyrimidine-7-carboxylic acid and protein kinase inhibitor intermediate |
| CN114524826A (en) * | 2022-02-18 | 2022-05-24 | 郑州猫眼农业科技有限公司 | Preparation process of 7-bromo-4-chlorothiophene [3,2-d ] pyrimidine |
| TW202342766A (en) | 2022-03-02 | 2023-11-01 | 瑞士商諾華公司 | Precision therapy for the treatment of cancer |
| WO2024033381A1 (en) | 2022-08-10 | 2024-02-15 | Vib Vzw | Inhibition of tcf4/itf2 in the treatment of cancer |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0402518D0 (en) * | 2004-02-05 | 2004-03-10 | Astrazeneca Ab | Therapeutic agents |
| GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| RU2528046C2 (en) * | 2004-06-24 | 2014-09-10 | Вертекс Фармасьютикалз Инкорпорейтед | Modulators of atp-binding cartridge transporters |
| MY146795A (en) | 2005-06-09 | 2012-09-28 | Novartis Ag | Process for the synthesis of organic compounds |
| US7989461B2 (en) | 2005-12-23 | 2011-08-02 | Amgen Inc. | Substituted quinazolinamine compounds for the treatment of cancer |
| AU2007227602A1 (en) * | 2006-03-16 | 2007-09-27 | Novartis Ag | Heterocyclic organic compounds for the treatment of in particular melanoma |
| US8633201B2 (en) | 2006-04-07 | 2014-01-21 | Boehringer Ingelheim International Gmbh | Thienopyrimidines having Mnk1/Mnk2 inhibiting activity for pharmaceutical compositions |
| WO2008044688A1 (en) * | 2006-10-11 | 2008-04-17 | Daiichi Sankyo Company, Limited | Urea derivative |
| KR101257158B1 (en) | 2008-05-23 | 2013-04-23 | 노파르티스 아게 | Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors |
| BRPI0921862A2 (en) * | 2008-12-05 | 2015-12-29 | Arqule Inc | raf inhibitors and their uses |
| WO2010101302A1 (en) | 2009-03-05 | 2010-09-10 | Takeda Pharmaceutical Company Limited | Thienopyrimidine as cdc7 kinase inhibitors |
| DE102009035754A1 (en) | 2009-07-24 | 2011-01-27 | Hartmetall-Werkzeugfabrik Paul Horn Gmbh | Cutting insert for a cutting tool for machining, in particular for high-feed milling |
| US20120157439A1 (en) | 2009-08-28 | 2012-06-21 | Genentech, Inc. | Raf inhibitor compounds and methods of use thereof |
| KR101147550B1 (en) | 2009-10-22 | 2012-05-17 | 한국과학기술연구원 | 2,7-Substituted thieno[3,2-d]pyrimidine compounds as protein kinase inhibitors |
| KR101094446B1 (en) | 2009-11-19 | 2011-12-15 | 한국과학기술연구원 | 2,4,7-Substituted thieno[3,2-d]pyrimidine compounds as protein kinase inhibitors |
| KR101483215B1 (en) * | 2010-01-29 | 2015-01-16 | 한미약품 주식회사 | Bicyclic heteroaryl derivatives having inhibitory activity for protein kinases |
| CA2786438C (en) | 2010-01-29 | 2015-10-13 | Hanmi Science Co., Ltd. | Thieno[3,2-d]pyrimidine derivatives having inhibitory activity on protein kinases |
| CN105367577B (en) * | 2010-07-13 | 2019-04-23 | 弗·哈夫曼-拉罗切有限公司 | Pyrazolo [1,5A] pyrimidine and thieno [3,2B] pyrimidine derivatives as IRAK4 regulator |
-
2012
- 2012-12-27 JP JP2014550010A patent/JP5797345B2/en active Active
- 2012-12-27 HU HUE12861811A patent/HUE045957T2/en unknown
- 2012-12-27 LT LT12861811T patent/LT2797927T/en unknown
- 2012-12-27 UA UAA201408629A patent/UA109614C2/en unknown
- 2012-12-27 EP EP19198802.1A patent/EP3617213A1/en active Pending
- 2012-12-27 PE PE2014001048A patent/PE20141404A1/en active IP Right Grant
- 2012-12-27 SG SG11201402765TA patent/SG11201402765TA/en unknown
- 2012-12-27 BR BR122019019582-0A patent/BR122019019582B1/en active IP Right Grant
- 2012-12-27 US US14/363,857 patent/US9156852B2/en not_active Ceased
- 2012-12-27 MY MYPI2014701742A patent/MY170988A/en unknown
- 2012-12-27 IN IN6101DEN2014 patent/IN2014DN06101A/en unknown
- 2012-12-27 AU AU2012363558A patent/AU2012363558C1/en active Active
- 2012-12-27 PL PL12861811T patent/PL2797927T3/en unknown
- 2012-12-27 US US15/783,240 patent/USRE47451E1/en active Active
- 2012-12-27 AR ARP120105010A patent/AR089489A1/en active IP Right Grant
- 2012-12-27 ES ES12861811T patent/ES2751608T3/en active Active
- 2012-12-27 WO PCT/KR2012/011571 patent/WO2013100632A1/en active Application Filing
- 2012-12-27 MX MX2014007230A patent/MX363659B/en unknown
- 2012-12-27 CA CA2859668A patent/CA2859668C/en active Active
- 2012-12-27 KR KR20120154061A patent/KR101490761B1/en active IP Right Grant
- 2012-12-27 SI SI201231684T patent/SI2797927T1/en unknown
- 2012-12-27 CN CN201280064739.8A patent/CN104039798B/en active Active
- 2012-12-27 RU RU2014131390A patent/RU2625799C2/en active
- 2012-12-27 RS RSP20191305 patent/RS59420B1/en unknown
- 2012-12-27 BR BR112014015720-0A patent/BR112014015720B1/en active IP Right Grant
- 2012-12-27 DK DK12861811T patent/DK2797927T3/en active
- 2012-12-27 RU RU2017124993A patent/RU2705577C2/en active
- 2012-12-27 SG SG10201701999QA patent/SG10201701999QA/en unknown
- 2012-12-27 PT PT128618113T patent/PT2797927T/en unknown
- 2012-12-27 EP EP12861811.3A patent/EP2797927B1/en active Active
- 2012-12-28 TW TW101151181A patent/TWI462927B/en active
-
2014
- 2014-06-16 MX MX2019003468A patent/MX2019003468A/en unknown
- 2014-06-26 CL CL2014001729A patent/CL2014001729A1/en unknown
- 2014-06-27 PH PH12014501504A patent/PH12014501504B1/en unknown
- 2014-06-29 IL IL233441A patent/IL233441B/en active IP Right Grant
- 2014-07-25 CO CO14162082A patent/CO7010840A2/en active IP Right Grant
- 2014-07-29 ZA ZA2014/05583A patent/ZA201405583B/en unknown
-
2015
- 2015-02-11 HK HK15101503.1A patent/HK1200833A1/en unknown
-
2019
- 2019-04-28 IL IL266285A patent/IL266285B/en unknown
- 2019-10-11 HR HRP20191840TT patent/HRP20191840T8/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20191840T8 (en) | THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES | |
| EP2528925A4 (en) | THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES | |
| PL3141552T3 (en) | Thienopyrimidine derivatives having inhibitory activity for protein kinase | |
| HRP20171724T1 (en) | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AS KINASE INHIBITORS | |
| IL225622A0 (en) | Furo[3,2-d] pyrimidine compounds | |
| EP2491043A4 (en) | 2,7-substituted thieno[3,2-d]pyrimidine compounds as protein kinase inhibitors | |
| ZA201307839B (en) | Pyrazolo[4,3-d] pyrimidines useful as kinase inhibitors | |
| CO6801740A2 (en) | Pyrrolo [2,3-d] pyrimidine tropomyosin-related kinase inhibitors | |
| IL231903A0 (en) | 5,7-substituted-imidazo[1,2-c]pyrimidines | |
| EP3409278B8 (en) | Heterocyclic protein kinase inhibitors | |
| EP2661437A4 (en) | 2,4-DIAMINO-6,7-DIHYDRO-5H-PYRROLO[2,3]PYRIMIDINE DERIVATIVES AS FAK/Pyk2 INHIBITORS | |
| IL227526A0 (en) | 6-cyclobutyl-1,5-dihydro-pyrazolo [3,4-d]pyrimidin-4-one derivatives their use as pde9a inhibitors | |
| ZA201403441B (en) | [1,2,3]triazolo[4,5-d]pyrimidine derivatives as agonists of the cannabinoid | |
| ZA201406323B (en) | Triazolo[4,5-d]pyrimidine derivatives | |
| IL232717A0 (en) | 3-cyanoaryl-1h-pyrrolo[2,3-b]pyridine derivatives | |
| PL2694513T3 (en) | Pyrazolo pyrimidine derivatives | |
| EP2876107A4 (en) | Isoquinoline-5-carboxamide derivative having inhibitory activity for protein kinase | |
| AU2011355362B2 (en) | 5-([1,2,3]Triazole-4-yl)-7H-pyrrolo[2,3-d]pyrimidine derivatives |